PetMed Express, Inc. (PETS) to Post Q3 2018 Earnings of $0.32 Per Share, Northcoast Research Forecasts
PetMed Express, Inc. (NASDAQ:PETS) – Equities research analysts at Northcoast Research upped their Q3 2018 EPS estimates for shares of PetMed Express in a research report issued on Tuesday. Northcoast Research analyst E. Snyder now anticipates that the company will post earnings of $0.32 per share for the quarter, up from their prior estimate of $0.30. Northcoast Research has a “Buy” rating and a $54.00 price objective on the stock. Northcoast Research also issued estimates for PetMed Express’ FY2018 earnings at $1.60 EPS, Q1 2019 earnings at $0.49 EPS, Q2 2019 earnings at $0.42 EPS, Q3 2019 earnings at $0.34 EPS, Q4 2019 earnings at $0.41 EPS and FY2019 earnings at $1.66 EPS.
Other equities analysts have also recently issued reports about the stock. Noble Financial reissued a “hold” rating on shares of PetMed Express in a research note on Wednesday, July 26th. Credit Suisse Group reissued an “underperform” rating and issued a $19.00 price objective on shares of PetMed Express in a research note on Monday, October 2nd. ValuEngine cut shares of PetMed Express from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. Zacks Investment Research cut shares of PetMed Express from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 25th. Finally, Craig Hallum reissued a “hold” rating and issued a $40.00 price objective (down from $43.00) on shares of PetMed Express in a research note on Monday, August 21st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $42.00.
PetMed Express (NASDAQ PETS) opened at $38.67 on Friday. The stock has a market cap of $781.01, a price-to-earnings ratio of 25.09, a price-to-earnings-growth ratio of 2.24 and a beta of 1.09. PetMed Express has a 12 month low of $19.21 and a 12 month high of $50.90.
PetMed Express (NASDAQ:PETS) last announced its quarterly earnings data on Monday, October 23rd. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.13. The company had revenue of $66.70 million for the quarter, compared to analysts’ expectations of $63.41 million. PetMed Express had a net margin of 11.58% and a return on equity of 31.46%. PetMed Express’s revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.24 EPS.
The business also recently announced a quarterly dividend, which was paid on Friday, November 17th. Shareholders of record on Monday, November 6th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, November 3rd. This represents a $0.80 annualized dividend and a dividend yield of 2.07%. PetMed Express’s payout ratio is currently 53.69%.
In other PetMed Express news, Director Ronald J. Korn sold 1,000 shares of the business’s stock in a transaction on Friday, October 27th. The shares were sold at an average price of $35.57, for a total transaction of $35,570.00. Following the sale, the director now directly owns 73,833 shares in the company, valued at approximately $2,626,239.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.00% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of PETS. Principal Financial Group Inc. boosted its position in shares of PetMed Express by 3.4% during the 1st quarter. Principal Financial Group Inc. now owns 166,478 shares of the company’s stock worth $3,353,000 after purchasing an additional 5,478 shares in the last quarter. Teachers Advisors LLC boosted its position in shares of PetMed Express by 1.8% during the 1st quarter. Teachers Advisors LLC now owns 61,884 shares of the company’s stock worth $1,246,000 after purchasing an additional 1,097 shares in the last quarter. Thrivent Financial For Lutherans boosted its position in shares of PetMed Express by 4.1% during the 1st quarter. Thrivent Financial For Lutherans now owns 11,530 shares of the company’s stock worth $232,000 after purchasing an additional 450 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of PetMed Express by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 1,075,251 shares of the company’s stock worth $21,656,000 after purchasing an additional 44,560 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of PetMed Express by 4.2% during the 1st quarter. Geode Capital Management LLC now owns 164,993 shares of the company’s stock worth $3,322,000 after purchasing an additional 6,582 shares in the last quarter. Institutional investors own 87.13% of the company’s stock.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.